Replies to post #179130 on Biotech Values

[BTH]

The data I am referring to in DLBCL Is this...



http://investors.karyopharm.com/releasedetail.cfm?ReleaseID=851593

If CUDC-907 could cure MM, Curis would choose CLL. If CUDC-907 worked 100% of the time in solids, Curis would choose liquid tumors.

Basic math: Curis doesn't know what theyre doing.

The 427 fiasco...they literally wasted 1.5 years because they decided to dose 2x the DLT dosing of Roche.

Now even companies like TLOG are lapping them in IAP programs, when Roche gave them one on a silver platter.

It's a Harvard Business School example of how incompetent management can destroy "potential".

Dan may be "gone", but he hired Ali....never forget that (he also hired the previous 2 CMO's that he fired later on...claiming that they were the ones that screwed everything up).